The studies that investigated the role of lncRNA-MEG3 in atherosclerosis and psoriasis did so on tissue samples (atherosclerotic or psoriatic plaques), whereas the studies that investigated its role in T2DM and RA used PBMCs or serum of the participants. This evidence concerns the gene MEG3 and rheumatoid arthritis.